Speaker: FDA approval of KXL System ‘a major advancement’

NEW ORLEANS — The FDA approval of the KXL System for corneal collagen cross-linking is a major advancement in the treatment of progressive keratoconus, according to a speaker here. “We as corneal specialists and our patients can look forward to use of corneal collagen cross-linking, which certainly is a major advancement in treatment of keratoconus,” Peter S. Hersh, MD, said during Cornea Day preceding the American Society of Cataract and Refractive Surgery meeting.